Clinical Trials Results - National Cancer Institute

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -8 of 8 Show results per page	View Search Criteria \| Help With Results

Last Modified: 5/10/2007


1.		Phase III Randomized Study of Vaccination with Ganglioside GM2 Conjugated to Key Hole Limpet Hemocyanin plus Immunologic Adjuvant QS21 vs High Dose Interferon Alfa-2b in Patients with High Risk Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				NCI				E-1694 CAN-NCIC-ME9, MDA-DM-E1694, MSKCC-96008, SWOG-9512, CAN-NCIC-E1694, MSKCC-E1694, SWOG-E1694, E1694, ME9

Last Modified: 8/14/2008 First Published: 4/1/2000


2.		Phase III Randomized Study of Postoperative GM2-KLH and QS21 Vaccination Versus Observation in Patients With Primary Cutaneous Stage II Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 to 80				Other				EORTC-18961 BMS-CA152-003, NCT00005052

Last Modified: 3/1/1995


3.		Phase II Pilot Study of Booster Vaccinations with GM2-KLH plus QS21 for Stage III/IV Melanoma (Summary Last Modified 03/95)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				any age								MSKCC-94009A1 NCI-V94-0458

Last Modified: 6/1/1995


4.		Phase II Pilot Study of Vaccination with GM2-KLH plus QS21 in Stage III/IV Melanoma (Summary Last Modified 06/95)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				no age specified				NCI				MSKCC-94041 NCI-H94-0471

Last Modified: 8/2/2007


5.		Phase II Randomized Study of Vaccination with GM-2 Ganglioside Conjugated to Keyhole Limpet Hemocyanin plus the Immunologic Adjuvant QS21 with vs without High-Dose Interferon alfa in High-Risk Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				E-2696 E2696

Last Modified: 5/1/1992


6.		Phase II Pilot Study of Vaccination with GM2 Covalently Attached to KLH plus the Immunological Adjuvant QS21 in Patients with Resected Stage III/IV Melanoma (Summary Last Modified 05/92)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				any age								MSKCC-91071 NCI-V91-0179

Last Modified: 6/1/1998 First Published: 12/1/1997


7.		Phase I Study of GM2-KLH Vaccine Plus the Immunological Adjuvant QS21 for Prostate Cancer (Summary Last Modified 06/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				18 and over				NCI				MSKCC-97097 NCI-G97-1340

Last Modified: 6/1/2000 First Published: 8/1/1998


8.		Phase I Study of GM2-KLH Vaccine Plus the Immunological Adjuvant QS21 for High Risk Breast Cancer Patients Lacking Identifiable Disease (Summary Last Modified 06/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				18 and over				NCI				MSKCC-97123 NCI-H98-0015, NCT00003357

Select All on One Page